Janssen To Market Biweekly Risperdal In Japan
This article was originally published in PharmAsia News
Executive Summary
Japan's Janssen Pharmaceutical plans to begin marketing in Japan a new injectable version of Risperdal (risperidone) for treating schizophrena by the end of June. The Johnson & Johnson subsidiary is counting on a biweekly injectable form of the drug to be more attractive to Japanese patients than a daily oral medicine now available. With the new version, Janssen also hopes to make a generic version of the daily drug less attractive. The biweekly version is to be marketed in Japan as Risperdal Consta. (Click here for more - a subscription may be required
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.